BR112021024139A2 - Composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo - Google Patents

Composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR112021024139A2
BR112021024139A2 BR112021024139A BR112021024139A BR112021024139A2 BR 112021024139 A2 BR112021024139 A2 BR 112021024139A2 BR 112021024139 A BR112021024139 A BR 112021024139A BR 112021024139 A BR112021024139 A BR 112021024139A BR 112021024139 A2 BR112021024139 A2 BR 112021024139A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
general formula
egfr
Prior art date
Application number
BR112021024139A
Other languages
English (en)
Inventor
Gang Cao
Houxing Fan
Yuli Xie
Original Assignee
Wigen Biomedicine Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Tech Shanghai Co Ltd filed Critical Wigen Biomedicine Tech Shanghai Co Ltd
Publication of BR112021024139A2 publication Critical patent/BR112021024139A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo. a presente invenção fornece um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, um método de preparação e aplicação do mesmo. os compostos podem seletivamente inibir a atividade de mutantes de receptor de fator de crescimento epidérmico (egfr) e mostram um bom efeito inibidor em relação ao egfr mutante e atividade antiproliferativa contra células cancerosas. dessa forma, podem ser usados para tratar tumores e doenças relacionadas.
BR112021024139A 2019-07-04 2020-07-02 Composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo BR112021024139A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910600229.1A CN112174961A (zh) 2019-07-04 2019-07-04 一类抑制egfr激酶的化合物及其制备方法和用途
PCT/CN2020/099916 WO2021000912A1 (zh) 2019-07-04 2020-07-02 一类抑制egfr激酶的化合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112021024139A2 true BR112021024139A2 (pt) 2022-01-11

Family

ID=73914611

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024139A BR112021024139A2 (pt) 2019-07-04 2020-07-02 Composto de fórmula geral (i) ou um sal farmaceuticamente aceitável do mesmo

Country Status (10)

Country Link
US (1) US11993598B2 (pt)
EP (1) EP3998268A4 (pt)
JP (1) JP2022539224A (pt)
KR (1) KR20220027817A (pt)
CN (2) CN112174961A (pt)
AU (1) AU2020299659A1 (pt)
BR (1) BR112021024139A2 (pt)
CA (1) CA3142071A1 (pt)
MX (1) MX2021013982A (pt)
WO (1) WO2021000912A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188747A1 (zh) * 2014-06-12 2015-12-17 南京圣和药业股份有限公司 作为egfr抑制剂的苯基取代的三嗪类化合物及其应用
US10329277B2 (en) * 2015-07-16 2019-06-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity
EP3399968B8 (en) * 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
CN110818690B (zh) * 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物

Also Published As

Publication number Publication date
WO2021000912A1 (zh) 2021-01-07
US11993598B2 (en) 2024-05-28
EP3998268A4 (en) 2023-06-21
JP2022539224A (ja) 2022-09-07
US20210230161A1 (en) 2021-07-29
EP3998268A1 (en) 2022-05-18
KR20220027817A (ko) 2022-03-08
CA3142071A1 (en) 2021-01-07
CN114026090A (zh) 2022-02-08
MX2021013982A (es) 2022-01-04
CN114026090B (zh) 2023-01-06
AU2020299659A1 (en) 2022-01-27
CN112174961A (zh) 2021-01-05

Similar Documents

Publication Publication Date Title
WO2020033413A3 (en) Modulators of ras gtpase
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
BR112022012585A2 (pt) Inibidores de formas mutantes de egfr
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
WO2018155916A3 (ko) 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
BR112017006713A2 (pt) inibidor de egfr, e preparação e aplicação do mesmo
CA2962914C (en) Compounds and compositions for modulating egfr mutant kinase activities
EA201790660A1 (ru) Ингибитор киназ
MX2016004360A (es) Inhibidores de kras g12c.
MA32485B1 (fr) Derives de pyridazine en tant qu'inhibiteurs de smo
MX342326B (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
PH12020552135A1 (en) Kdm1a inhibitors for the treatment of disease
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
MX2021011606A (es) Compuestos dirigidos a prmt5.
BRPI0514390A (pt) enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
WO2019177374A8 (ko) 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
CA2902116C (en) Pyrrolopyridine derivatives and their use as inhibitors of ssao activity
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
EP3811946A4 (en) USE OF A CDK4/6 INHIBITOR IN COMBINATION WITH AN EGFR INHIBITOR IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF TUMOR DISEASES
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
BRPI0514398A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para a produção de um efeito inibidor de eg5 em um animal de sangue quente, para a produção de um efeito anti-proliferativol em um animal de sangue quente e para tratamento de doença, e, composição farmacêutica
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
WO2020128614A8 (en) Method for treating interstital lung disease